Mutations within the tumour suppressor gene p53 are not confined to a late event in prostate cancer progression: a review of the evidence

被引:33
作者
Downing, SR
Jackson, P
Russell, PJ
机构
[1] Prince Wales Hosp, Oncol Res Ctr, Randwick, NSW 2031, Australia
[2] Univ New S Wales, Fac Med, Kensington, NSW 2033, Australia
来源
UROLOGIC ONCOLOGY | 2001年 / 6卷 / 03期
关键词
p53; mutations; prostate cancer; tumour progression;
D O I
10.1016/S1078-1439(00)00119-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mutations in the p53 tumour suppressor gene are generally believed to be a late event in the progression of prostate cancer, and are associated with androgen independence, metastasis. and a worse prognosis. In this review, we examine the current literature available on p53 mutations and focus on stages A (T1) and B (T2) of prostate cancer. We report here that p53 mutations can he found in approximately one third of prostate cancers that are clinically localized to the prostate. In addition, high levels of p53 mutation are found in normal prostate tissue of prostate cancer patients, prostatic intracpithelial neoplasia, and benign prostatic hyperplasia. The limitations of techniques used to determine p53 mutations are discussed. as well as other modes of p53 loss in early stage prostate cancer. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:103 / 110
页数:8
相关论文
共 130 条
  • [1] Anderson M, 1997, J MED VIROL, V52, P8, DOI 10.1002/(SICI)1096-9071(199705)52:1<8::AID-JMV2>3.0.CO
  • [2] 2-8
  • [3] ANWAR K, 1992, CANCER RES, V52, P5991
  • [4] Bauer JJ, 1995, CLIN CANCER RES, V1, P1295
  • [5] Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer
    Bauer, JJ
    Sesterhenn, IA
    Mostofi, FK
    McLeod, DG
    Srivastava, S
    Moul, JW
    [J]. JOURNAL OF UROLOGY, 1996, 156 (04) : 1511 - 1516
  • [6] Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18
    Bello, D
    Webber, MM
    Kleinman, HK
    Wartinger, DD
    Rhim, JS
    [J]. CARCINOGENESIS, 1997, 18 (06) : 1215 - 1223
  • [7] BOOKSTEIN R, 1993, CANCER RES, V53, P3369
  • [8] Bostwick DG, 1996, PROSTATE, V29, P117
  • [9] Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy
    Brewster, SF
    Oxley, JD
    Trivella, M
    Abbott, CD
    Gillatt, DA
    [J]. JOURNAL OF UROLOGY, 1999, 161 (04) : 1238 - 1243
  • [10] Bright RK, 1997, CANCER RES, V57, P995